



PRESS RELEASE DECEMBER 22nd 2011

MOBERG DERMA TERMINATES COLLABORATION IN CANADA

Moberg Derma AB (STO: MOB) and Medical Futures Inc. have agreed that the distribution agreement between the parties shall cease, and that cooperation ends. The agreement gave the distributor the exclusive right to market and sell Emtrix[®] in Canada.

Moberg Derma regains all rights to Emtrix[®] in Canada. The distributor has the right to sell off its stock for a period.

"Sales in Canada have not met expectations and we have therefore agreed to terminate the agreement. We aim to select a new distributor with strong consumer marketing capabilities", says Peter Wolpert, CEO of Moberg Derma.

For further information, please contact:

Peter Wolpert, President and CEO

Telephone: +46 8 522 307 00

Mobile: +46 735 71 35

E-mail: peter.wolpert@mobergderma.se

Magnus Persson, IR

Mobile: +46 73-355 26 01

E-mail: magnus.persson@mobergderma.se

About this information

Moberg Derma discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication on at 3:00 pm (CET) on December 22nd, 2011.

About Moberg Derma

Moberg Derma AB (publ), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company's products are based on proven compounds, which reduce time to market, development costs and risk. Moberg Derma's first product NaloxTM/Emtrix[®] - for nail disorders - became the Nordic market leader directly after launch in autumn 2010 and international launch is ongoing. The portfolio includes approved and launched products to projects in the preclinical and clinical phase. The company began operations at the Karolinska Institute in Stockholm in 2006. The share of Moberg Derma is quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergderma.se